# A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

> **NCT05367401** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Myelodysplastic Syndromes
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Sabatolimab
- **DRUG:** Magrolimab
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT05367401
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12-20
- **Primary completion:** 2029-10-26
- **Final completion:** 2029-10-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** waiting for update from Study Lead
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05367401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05367401, "A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05367401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*